Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Biol Chem. Jul 27, 2023; 14(4): 72-83
Published online Jul 27, 2023. doi: 10.4331/wjbc.v14.i4.72
Published online Jul 27, 2023. doi: 10.4331/wjbc.v14.i4.72
In silico evidence of Remdesivir action in blood coagulation cascade modulation in COVID-19 treatment
Luis Gustavo Pagliarin, Lucca Miketen de Oliveira, Valentina Nunes Fontoura dos Anjos, Cristiano de Bem Torquato de Souza, Cinthia Façanha Wendel, Anderson Dillmann Groto, Kádima Nayara Teixeira, Campus Toledo, Universidade Federal do Paraná, Toledo 85.919-899, Paraná, Brazil
Gabrielle Caroline Peiter, Kádima Nayara Teixeira, Programa Multicêntrico de Pós-graduação em Bioquímica e Biologia Molecular - Setor Palotina, Universidade Federal do Paraná, Palotina 85.950-000, Paraná, Brazil
Fabrício Freire de Melo, Instituto Multidisciplinar em Saúde - Campus Anísio Teixeira, Universidade Federal da Bahia, Vitória da Conquista 45.029-094, Bahia, Brazil
Author contributions: Pagliarin LG, Oliveira LM, Anjos VNF, and Souza CBT performed the experiments, analyzed the results, and wrote the manuscript; Peiter GC, Wendel CF, and Groto AD performed the experiments; Melo FF performed the critical analysis of the results; Teixeira KN interpreted the data, performed the critical analysis of the results, corrected the manuscript, and coordinated the study; all authors approved the final version of the manuscript.
Institutional review board statement: This study used data from three-dimensional structures deposited in public online databases.
Conflict-of-interest statement: The authors state that there is no conflict of interest of any kind with regard to this study.
Data sharing statement: This study was developed in silico and no patient data or data from medical records were used in this study.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kádima Nayara Teixeira, PhD, Professor, Campus Toledo, Universidade Federal do Paraná, Max Planck 3796, Toledo 85.919-899, Paraná, Brazil. kadimateixeira@ufpr.br
Received: December 30, 2022
Peer-review started: December 30, 2022
First decision: April 13, 2023
Revised: April 30, 2023
Accepted: July 3, 2023
Article in press: July 3, 2023
Published online: July 27, 2023
Processing time: 206 Days and 8.3 Hours
Peer-review started: December 30, 2022
First decision: April 13, 2023
Revised: April 30, 2023
Accepted: July 3, 2023
Article in press: July 3, 2023
Published online: July 27, 2023
Processing time: 206 Days and 8.3 Hours
Core Tip
Core Tip: In the initial period of the emergence of coronavirus disease 2019, bioinformatics tools filled the need for rapid knowledge about the severe acute respiratory syndrome coronavirus 2 and research in search of drug treatment, since experimental research takes time that was not available. Bioinformatics continues to be used for the same purpose in this study, remembering that this methodology does not rule out either in vivo or in vitro testing.